Dr. He is the leading scientist studying proteomics in China. He was the founder of CNHUPO and among the first group of people who founded HUPO in 2001. He was the first Chinese scientist who led an international consortium-Human Liver Proteome Project (HLPP), and the founder of Beijing Proteome Research Center, Phoenix Center (proteomics) and Institutes of Biomedical Sciences Fudan University. As the chief scientist, he has been propelling HLPP to the China Human Proteome Project (CNHPP), to create an encyclopedia of proteins in the human body under physiological and pathological conditions. Recently, his team stratified early hepatocarcinoma (HCC) into 3 proteomic subtypes with different clinical outcome. Some drug targetable proteins have been demonstrated useful in identifying patients with HCC who could potentially benefit from targeted treatment in further clinical trials. These studies demonstrated the proteomic analysis as an independent powerful tool in cancer molecular subtyping, indicating that the era of “Proteome Driven Precision Medicine (PDPM)” is coming.
Abstracts this author is presenting: